

CASE CT-2731A CIP1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Samuel J. DuBoff
Type or print name

Signature

April 8, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

WANG ET AL.

APPLICATION NO: 10/762,108

FILED: JANUARY 21, 2004

FOR: INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-
ALKENYL PIPERIDINE AMIDES

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Some of the listed references are of record in parent Application No. 10/425,370 filed April 29, 2003, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, copies of the other cited references (WO 97/24350 and WO 02/04440) are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7787


Samuel J. DuBoff
Attorney for Applicants
Reg. No. 25,969

Date: 4/8/04

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2731A CIP1
APPLICATION NO.
10/762,108
APPLICANT
Wang et al.
FILING DATE
January 21, 2004

Sheet 1 of 2

Group --

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,124,327	6/23/92	W. J. Greenlee, et al			
	AB	5,424,329	6/13/95	D. H. Boschelli, et al			
	AC	5,023,265	6/11/91	M. H. Scherlock, et al			
	AD	6,469,006	10/22/02	W. S. Blair, et al			
	AE	6,476,034	11/5/02	T. Wang, et al			
	AF	6,573,262	6/3/03	O. B. Wallace, et al			
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI	EP 0530907A1	3/10/93	European Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 93/01181	1/21/93	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 95/04742	2/16/95	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 96/11929	4/25/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 02/062423	8/15/02	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 97/24350 ✓	7/10/97	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 02/04440 ✓	1/17/02	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AS	M. Font, et al, "Indoles and Pyridazino[4,5-b]Indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase," EUR. J. MED. CHEM., 30 , pp. 963-971, 1995
AT	D. L. Romero, et al, J. MED. CHEM., 36 , pp. 1505-1508, 1993
AU	S. D. Young, et al, "2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 5 (5), pp. 491-496, 1995

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2731A CIP1
APPLICATION NO.
10/762,108
APPLICANT
Wang et al.
FILING DATE
January 21, 2004

Group --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AV	M. J. Genin, et al, "Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs," J. MED. CHEM., 39 , pp. 5267-5275, 1996
AW	R. Silvestri, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 9 , pp. 139-148, 1998
AX	A. Fredenhagen, et al, "Semicochlordinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinase Related to Asterriquinones Produced by the Fungus <i>Chrysosporium Merdarium</i> ," JOURNAL OF ANTIBIOTICS, 50 (5), pp. 395-401, 1997
AY	M. Kato, et al, "New 5-HT ₃ (Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives," CHEM. PHARM. BULL., 43 (8), pp. 1351-1357, 1995
AZ	V. Levacher, et al, "Broadening in the Scope of NADH Models by Using Chiral and Non-Chiral Pyrrolo [2,3-b]Pyridine Derivatives," TETRAHEDRON, 47 (3), pp. 429-440, 1991
BA	
BB	
BC	
BD	
BE	
BF	
BG	
BH	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.